Literature DB >> 31728843

Difficulty of predicting early-onset super-imposed preeclampsia in pregnant women with hemodialysis due to diabetic nephropathy by serum levels of sFlt-1, PlGF, and sEng.

Hiroyuki Morisawa1, Chikako Hirashima1, Miho Sano1, Shiho Nagayama1, Hironori Takahashi1, Koumei Shirasuna2, Akihide Ohkuchi3.   

Abstract

There are few case reports in which circulating levels of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng) were measured before the onset of super-imposed preeclampsia in women with hemodialysis. A 40-year-old Japanese nulliparous women with hemodialysis due to diabetic nephropathy became pregnant by frozen embryo transfer. Intensive hemodialysis was started at 5 weeks of gestation. Her blood pressure (BP) in the first trimester was around 130/80 mmHg. At 20+3 weeks, she was admitted for close monitoring; her BP was 137/75 mmHg. Her BP increased to 157/88 mmHg at 31+2 weeks, and nifedipine at 20 mg/day was started at 31+6 weeks. However, the serial longitudinal measurements of sFlt-1, PlGF, and sEng did not predict the onset of super-imposed preeclampsia. Cesarean section was performed at 33+6 weeks due to uncontrollable hypertension. A healthy female infant weighing 2138 g was delivered. As for the changes of biomarkers between just before and just after hemodialysis, sFlt-1 was significantly higher just after compared with just before hemodialysis (5774 ± 1875 pg/mL vs. 2960 ± 905 pg/mL, respectively, p < 0.001). PlGF was also significantly higher just after compared with just before hemodialysis (2227 ± 1038 pg/mL vs. 1377 ± 614 pg/mL, respectively, p < 0.001). However, the sFlt-1/PlGF ratio and sEng levels were not significantly different between just before and just after hemodialysis (p = 0.115, p = 0.672, respectively). In conclusion, prediction of early-onset super-imposed preeclampsia using angiogenic and anti-angiogenic markers in pregnant women with hemodialysis might be difficult.

Entities:  

Keywords:  Hemodialysis; Placental growth factor; Preeclampsia; Soluble endoglin; Soluble fms-like tyrosine kinase 1

Mesh:

Substances:

Year:  2019        PMID: 31728843      PMCID: PMC7148397          DOI: 10.1007/s13730-019-00435-y

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  19 in total

1.  Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors.

Authors:  Chikako Hirashima; Akihide Ohkuchi; Kayo Takahashi; Hirotada Suzuki; Mika Yoshida; Takako Ohmaru; Kazuo Eguchi; Haruko Ariga; Shigeki Matsubara; Mitsuaki Suzuki
Journal:  Hypertens Res       Date:  2010-11-04       Impact factor: 3.872

2.  Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.

Authors:  Akihide Ohkuchi; Chikako Hirashima; Shigeki Matsubara; Kayo Takahashi; Yoshio Matsuda; Mitsuaki Suzuki
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

3.  Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling.

Authors:  S Drewlo; K Levytska; M Sobel; D Baczyk; S J Lye; J C P Kingdom
Journal:  J Thromb Haemost       Date:  2011-12       Impact factor: 5.824

4.  Obstetric outcome in pregnant women on long-term dialysis: a case series.

Authors:  Claudio Luders; Manuel Carlos Martins Castro; Silvia Maria Titan; Isac De Castro; Rosilene Mota Elias; Hugo Abensur; João Egidio Romão
Journal:  Am J Kidney Dis       Date:  2010-04-10       Impact factor: 8.860

Review 5.  Dialysis in pregnancy.

Authors:  Kate Wiles; Leandro de Oliveira
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2018-11-27       Impact factor: 5.237

6.  Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis.

Authors:  Hui Yi Shan; Sarosh Rana; Franklin H Epstein; Isaac E Stillman; S Ananth Karumanchi; Mark E Williams
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

7.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

8.  Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1.

Authors:  Frédéric Lavainne; Emmanuelle Meffray; Ruth J Pepper; Mélanie Néel; Catherine Delcroix; Alan D Salama; Fadi Fakhouri
Journal:  Nephrol Dial Transplant       Date:  2014-02-09       Impact factor: 5.992

9.  Pregnancy during hemodialysis: perinatal outcome in our cases.

Authors:  D Eroğlu; A Lembet; F N Ozdemir; T Ergin; F Kazanci; E Kuşcu; M Haberal
Journal:  Transplant Proc       Date:  2004 Jan-Feb       Impact factor: 1.066

10.  Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination.

Authors:  Henning Hagmann; Verena Bossung; Abdel Ali Belaidi; Alexander Fridman; S Ananth Karumanchi; Ravi Thadhani; Bernhard Schermer; Peter Mallmann; Guenter Schwarz; Thomas Benzing; Paul T Brinkkoetter
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.